Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Claudiani

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
British Journal of Haematology|December 28, 2020
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemiaSimone Claudiani, Jane F Apperley, Richard Szydlo, et al.
American Journal of Hematology|March 4, 2024
Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocationsSimone Claudiani, Lynette Chee, Fiona Fernando, et al.
Cardio-Oncology (London, England)|July 15, 2024
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk scoreFiona Fernando, Maria Sol Andres, Simone Claudiani, et al.
Leukemia & Lymphoma|January 24, 2022
Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence studySimone Claudiani, Eleanor L Parker, Dragana Milojkovic, et al.
European Journal of Haematology|April 11, 2022
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the NetherlandsSimone Claudiani, Jeroen J W M Janssen, Jenny Byrne, et al.
British Journal of Haematology|October 6, 2020
Identification of genetic targets in acute myeloid leukaemia for designing targeted therapyClinton C Mason, Carme R Fiol, Monika J Baker, et al.
Hematological Oncology|December 4, 2014
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosisSimone Claudiani, Sarah Marktel, Simona Piemontese, et al.
British Journal of Haematology|March 9, 2026
Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemiaSimone Claudiani, Silvia Metelli, Afzal Khan, et al.
Haematologica|May 11, 2019
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitorsGeorgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, et al.
Leukemia|December 17, 2022
COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsDragana Milojkovic, Catherine J Reynolds, Diana Mūnoz Sandoval, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|December 28, 2020
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemiaSimone Claudiani, Jane F Apperley, Richard Szydlo, et al.
American Journal of Hematology|March 4, 2024
Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocationsSimone Claudiani, Lynette Chee, Fiona Fernando, et al.
Cardio-Oncology (London, England)|July 15, 2024
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk scoreFiona Fernando, Maria Sol Andres, Simone Claudiani, et al.
Leukemia & Lymphoma|January 24, 2022
Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence studySimone Claudiani, Eleanor L Parker, Dragana Milojkovic, et al.
European Journal of Haematology|April 11, 2022
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the NetherlandsSimone Claudiani, Jeroen J W M Janssen, Jenny Byrne, et al.
British Journal of Haematology|October 6, 2020
Identification of genetic targets in acute myeloid leukaemia for designing targeted therapyClinton C Mason, Carme R Fiol, Monika J Baker, et al.
Hematological Oncology|December 4, 2014
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosisSimone Claudiani, Sarah Marktel, Simona Piemontese, et al.
British Journal of Haematology|March 9, 2026
Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemiaSimone Claudiani, Silvia Metelli, Afzal Khan, et al.
Haematologica|May 11, 2019
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitorsGeorgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, et al.
Leukemia|December 17, 2022
COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsDragana Milojkovic, Catherine J Reynolds, Diana Mūnoz Sandoval, et al.
Pageof 4